Smith & Nephew plc (NYSE:SNN) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Smith & Nephew plc (NYSE:SNN) have been given a consensus rating of “Hold” by the five ratings firms that are presently covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and two have issued a buy rating on the company.

Separately, StockNews.com cut shares of Smith & Nephew from a “strong-buy” rating to a “buy” rating in a research note on Monday, May 13th.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of SNN. Scharf Investments LLC increased its stake in shares of Smith & Nephew by 0.5% during the first quarter. Scharf Investments LLC now owns 2,996,264 shares of the medical equipment provider’s stock valued at $75,985,000 after buying an additional 15,930 shares during the period. American Century Companies Inc. lifted its position in shares of Smith & Nephew by 343.5% in the 3rd quarter. American Century Companies Inc. now owns 2,364,037 shares of the medical equipment provider’s stock worth $58,557,000 after purchasing an additional 1,830,965 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of Smith & Nephew by 3.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,343,712 shares of the medical equipment provider’s stock valued at $36,656,000 after purchasing an additional 44,445 shares in the last quarter. Brandes Investment Partners LP bought a new position in Smith & Nephew in the fourth quarter worth approximately $29,884,000. Finally, Wells Fargo & Company MN lifted its holdings in Smith & Nephew by 20.9% during the fourth quarter. Wells Fargo & Company MN now owns 1,003,050 shares of the medical equipment provider’s stock worth $27,363,000 after buying an additional 173,448 shares during the period. 25.64% of the stock is currently owned by hedge funds and other institutional investors.

Smith & Nephew Stock Performance

NYSE SNN opened at $24.87 on Friday. The business’s 50 day moving average price is $24.98 and its 200-day moving average price is $26.30. Smith & Nephew has a fifty-two week low of $21.52 and a fifty-two week high of $32.28. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.77 and a quick ratio of 0.72.

Smith & Nephew Dividend Announcement

The business also recently announced a semi-annual dividend, which was paid on Wednesday, May 22nd. Stockholders of record on Tuesday, April 2nd were given a dividend of $0.462 per share. This represents a dividend yield of 2.8%. The ex-dividend date was Monday, April 1st.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.